PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.92%
Both companies show declining cash positions (-42.92% vs GNPX's -61.17%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-42.83%
Cash + STI yoy 0.5-0.75x GNPX's -61.17%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.38%
0.75-0.9x GNPX's -50.62%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-9.44%
Both GNPX and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.57%
≥ 1.5x GNPX's -4.04%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
Similar yoy to GNPX's -36.31%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
31.92%
Less than half of GNPX's -38.99%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.79%
Less than half of GNPX's 144.34%. David Dodd sees fewer expansions in other current obligations.
-7.19%
Less than half of GNPX's 13.75%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.19%
Less than half of GNPX's 13.75%. David Dodd sees far fewer liability expansions relative to competitor.
1.19%
Less than half of GNPX's 37.22%. David Dodd sees fewer share issuances vs. competitor.
-6.33%
≥ 1.5x GNPX's -2.94%. David Dodd sees higher yoy retained profits than competitor.
-55.74%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-181.05%
≥ 1.5x GNPX's -64.03%. David Dodd sees stronger capital base growth than competitor.
-39.92%
Similar yoy to GNPX's -36.31%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.34%
50-75% of GNPX's 61.17%. Bruce Berkowitz notes comparatively lower net debt expansion.